Is POTS Hereditary? The Genetics of Familial Dysautonomia

One of the most common questions from newly diagnosed POTS patients is whether their condition is hereditary — and whether their children or siblings are at risk. The answer is nuanced: POTS clearly has a genetic component, as evidenced by its familial clustering, but the specific genes involved are incompletely understood, and POTS is likely genetically heterogeneous, meaning different genetic pathways can produce the same clinical syndrome.

Evidence for a Genetic Basis

Several lines of evidence support a genetic contribution to POTS:

Familial clustering. Studies consistently find that POTS patients are significantly more likely than the general population to have first-degree relatives with POTS or other forms of dysautonomia. One survey found that approximately 30% of POTS patients reported a first-degree relative with similar symptoms.

Concordance in twins. While formal twin studies of POTS are limited, case reports of identical twins with POTS support a genetic contribution.

Association with genetic conditions. POTS is strongly associated with hEDS/HSD, Marfan syndrome, and other connective tissue disorders that have known genetic bases. In these cases, the genetic risk for POTS is mediated through the connective tissue disorder.

Candidate gene studies. Several genes have been identified in POTS patients at higher frequencies than in the general population, including variants in NET (norepinephrine transporter), ADRB2 (beta-2 adrenergic receptor), and KCNJ5 (a potassium channel gene).

The NET (Norepinephrine Transporter) Connection

The most extensively studied genetic finding in POTS is a variant in the NET gene (SLC6A2), which encodes the norepinephrine transporter — the protein responsible for reuptaking norepinephrine from the synaptic cleft back into presynaptic neurons. A loss-of-function variant in NET was identified in a family with multiple members affected by POTS, and subsequent studies have found NET variants in a subset of POTS patients.

Impaired NET function leads to elevated synaptic norepinephrine, which is consistent with the elevated plasma norepinephrine levels seen in hyperadrenergic POTS. SNRIs (serotonin-norepinephrine reuptake inhibitors) work by blocking NET, which is why some POTS patients paradoxically worsen on SNRIs — if NET is already dysfunctional, further blocking it may worsen norepinephrine accumulation.

POTS Subtypes and Their Genetic Associations

Different POTS subtypes may have different genetic underpinnings:

What Genetic Testing Can and Cannot Tell You

Currently, there is no single genetic test that diagnoses POTS or predicts POTS risk. However, genetic testing can be informative in specific contexts:

Useful genetic testing for POTS patients:

• EDS subtype panel (rules out vascular EDS, classical EDS)
• MTHFR, COMT, MAO-A, HNMT, DAO (informs treatment and supplement choices)
• HFE (screens for hemochromatosis)
• Whole exome sequencing (in research settings or for patients with atypical presentations)

Not currently useful:

• NET variants (not clinically validated for diagnosis or treatment guidance)
• POTS-specific panels (no validated panel exists)

Inheritance Patterns and Family Risk

Because POTS is genetically heterogeneous, inheritance patterns vary by underlying cause:

• hEDS-associated POTS: Autosomal dominant inheritance of hEDS; first-degree relatives have ~50% risk of hEDS and elevated risk of POTS
• NET variant-associated POTS: Autosomal dominant; first-degree relatives have ~50% risk of carrying the variant
• Sporadic POTS: No clear inheritance pattern; family risk is elevated above background but not as high as for monogenic forms

Key Takeaways

POTS has a significant genetic component, but the genetics are complex and incompletely understood. Family members of POTS patients — particularly first-degree relatives — have elevated risk and should be monitored for symptoms of orthostatic intolerance. Genetic testing is most useful for identifying treatable comorbidities (hemochromatosis, specific EDS subtypes) and informing treatment choices (COMT, MAO-A, MTHFR variants) rather than for diagnosing POTS itself.

This article is for informational purposes only and does not constitute medical advice.